A Psyrri1, T Rampias2, J B Vermorken3. 1. Department of Medicine, Section of Medical Oncology, Attikon University Hospital, Athens, Greece. Electronic address: psyrri237@yahoo.com. 2. Department of Surgery (Otolaryngology), Yale University School of Medicine, New Haven, USA. 3. Department of Medical Oncology, Antwerp University Hospital, Edegem, Belgium.
Abstract
BACKGROUND: Squamous cell carcinoma of the head and neck (SCCHN) was traditionally associated with smoking and alcohol use; however, human papillomavirus (HPV) infection has recently been implicated as a novel risk factor for oropharyngeal tumors. Furthermore, HPV-associated oropharyngeal carcinoma (OPC) appears to be a distinct entity with different epidemiology, biology, and clinical outcomes. METHODS: Here, we comprehensively review the existing data regarding HPV status and prognostic or predictive outcomes in both the locoregionally advanced (LA) and recurrent/metastatic (RM) disease setting and discuss ongoing trials that may eventually impact the treatment of patients with HPV-positive (HPV+) SCCHN. RESULTS: A body of retrospective and prospective data established an association between HPV+ OPC and better survival, particularly for LA disease. Current data on RM disease are limited, but they also suggest prognostic significance for HPV. CONCLUSIONS: Better outcomes in HPV+ LA disease may allow for less aggressive treatment in the future, and several trials are evaluating deintensified regimens in patients with HPV+, LA OPC; it should be emphasized that deintensification strategies are appropriate only in a clinical research setting and only for selected subgroups of HPV+ patients. In addition, HPV-targeted strategies, such as vaccines, are currently undergoing clinical evaluation. On the other hand, the prognostic impact of HPV in RM disease requires further validation before any modifications in treatment can be made. Likewise, the predictive significance of HPV status in both disease settings remains to be defined. CLINICAL TRIAL NUMBERS: NCT00226239, NCT00301028, NCT00387127, NCT00410826, NCT00503997, NCT00514943, NCT00544414, NCT00768664, NCT00939627, NCT01084083, NCT01302834, NCT01687413, NCT01706939.
BACKGROUND: Squamous cell carcinoma of the head and neck (SCCHN) was traditionally associated with smoking and alcohol use; however, human papillomavirus (HPV) infection has recently been implicated as a novel risk factor for oropharyngeal tumors. Furthermore, HPV-associated oropharyngeal carcinoma (OPC) appears to be a distinct entity with different epidemiology, biology, and clinical outcomes. METHODS: Here, we comprehensively review the existing data regarding HPV status and prognostic or predictive outcomes in both the locoregionally advanced (LA) and recurrent/metastatic (RM) disease setting and discuss ongoing trials that may eventually impact the treatment of patients with HPV-positive (HPV+) SCCHN. RESULTS: A body of retrospective and prospective data established an association between HPV+ OPC and better survival, particularly for LA disease. Current data on RM disease are limited, but they also suggest prognostic significance for HPV. CONCLUSIONS: Better outcomes in HPV+ LA disease may allow for less aggressive treatment in the future, and several trials are evaluating deintensified regimens in patients with HPV+, LA OPC; it should be emphasized that deintensification strategies are appropriate only in a clinical research setting and only for selected subgroups of HPV+ patients. In addition, HPV-targeted strategies, such as vaccines, are currently undergoing clinical evaluation. On the other hand, the prognostic impact of HPV in RM disease requires further validation before any modifications in treatment can be made. Likewise, the predictive significance of HPV status in both disease settings remains to be defined. CLINICAL TRIAL NUMBERS: NCT00226239, NCT00301028, NCT00387127, NCT00410826, NCT00503997, NCT00514943, NCT00544414, NCT00768664, NCT00939627, NCT01084083, NCT01302834, NCT01687413, NCT01706939.
Authors: Theresa Guo; Jesse R Qualliotine; Patrick K Ha; Joseph A Califano; Young Kim; John R Saunders; Ray G Blanco; Gypsyamber D'Souza; Zhe Zhang; Christine H Chung; Ana Kiess; Christine G Gourin; Wayne Koch; Jeremy D Richmon; Nishant Agrawal; David W Eisele; Carole Fakhry Journal: Cancer Date: 2015-03-17 Impact factor: 6.860
Authors: Efterpi Kostareli; Thomas Hielscher; Manuela Zucknick; Lorena Baboci; Gunnar Wichmann; Dana Holzinger; Oliver Mücke; Michael Pawlita; Annarosa Del Mistro; Paolo Boscolo-Rizzo; Maria Cristina Da Mosto; Giancarlo Tirelli; Peter Plinkert; Andreas Dietz; Christoph Plass; Dieter Weichenhan; Jochen Hess Journal: Epigenetics Date: 2016-01-19 Impact factor: 4.528
Authors: Narges Tehrany; Julia Kitz; Margret Rave-Fränk; Stephan Lorenzen; Li Li; Stefan Küffer; Clemens F Hess; Peter Burfeind; Holger M Reichardt; Martin Canis; Tim Beissbarth; Hendrik A Wolff Journal: Strahlenther Onkol Date: 2015-01-10 Impact factor: 3.621
Authors: Angela L Mazul; Nidia Rodriguez-Ormaza; James M Taylor; Dipan D Desai; Paul Brennan; Devasena Anantharaman; Tarik Gheit; Massimo Tommasino; Behnoush Abedi-Ardekani; Andrew F Olshan; Jose P Zevallos Journal: Oral Oncol Date: 2016-09-06 Impact factor: 5.337
Authors: Wesley H Stepp; Douglas Farquhar; Siddharth Sheth; Angela Mazul; Mohammed Mamdani; Trevor G Hackman; D Neil Hayes; Jose P Zevallos Journal: JAMA Otolaryngol Head Neck Surg Date: 2018-11-01 Impact factor: 6.223